Educational Programme

EBAC ACCREDITATION PENDING

April 24, 2017 13:00
Why TG-rich lipoproteins/non-HDL-Cholesterol matter when assessing CVD risk?

Chair:
  • Kausik Ray
  • Jan Borén

Atherogenic dyslipidemia (AD)

Alberto Zambon, Padova, Italy

Fibrates in the management of AD and CVD risk

Michal Vrablík, Prague, Czech Republic

EAS have independently organised all matters related to this 60-minute Programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from Mylan in support of the Programme.

April 23, 2017 14:00
Progress in understanding the role of nutrition in prevention of atherosclerosis

Chair:
  • Olov Wiklund
  • Alberico L. Catapano

Life time exposure to LDL-cholesterol is it the key to CVD risk?

Brian A. Ference, Detroit, USA

Nordic and Mediterranean diet patterns from the CVD point of view

Ursula Schwab, Kuopio, Finland

The new EAS/ESC Guidelines on diet and lifestyle in cardiovascular prevention

Gabriele Ricardi, Naples, Italy

EAS have independently organised all matters related to this 90-minute Programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from Unilever/BASF/Raisio in support of the Programme.

April 25, 2017 13:00
Nutraceuticals for early control of dyslipidemia: the clinical evidence

Chair:
  • Eric Bruckert

The clinical evidence: Meta-analysis of the RCT

Matteo Pirro, Perugia, Italy

Typical clinical cases: who may benefit?

Eric Bruckert, Paris, France

Updates on the guidelines. Which role for nutraceuticals?

Emilio Ros, Barcelona, Spain

EAS have independently organised all matters related to this 60-minute Programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from Mylan in support of the Programme.

April 24, 2017 13:00
LAL deficiency

Chair:
  • Maurizio Averna
  • Petri Kovanen

Lysosomal acid lipase deficiency – an underdiagnosed and misdiagnosed cause of dyslipidemia and liver dysfuntion

Maurizio Averna, Palermo, Italy

Enzymatic replacement therapy for lysosomal adic lipase deficiency in adult patients with lysosomal acid lipase deficiency

Reena Sharma, Salford, United Kingdom

EAS have independently organised all matters related to this 60-minute Programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from Alexion in support of the Programme.

April 24, 2017 14:00
CVD prevention strategies

Chair:
  • Michal Vrablík
  • Maciej Banach

The value of generic medicines

Gianni Corrao, Perugia, Italy

Combination therapy a better way to treat?

Lale Tokozoglu, Ankara, Turkey

EAS have independently organised all matters related to this 60-minute Programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from Sanofi Generics in support of the Programme.